Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
178 stopped studies mapped to Triple-Negative Breast Carcinoma and descendants · 97% state a reason
Over the 178 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | Phase 1 | withdrawn | Mar 20, 2023 | Dana-Farber Cancer Institute | On hold | Other (stated, no rule matched) |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus… | Phase 3 | terminated | Apr 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel… | Phase 3 | suspended | Dec 23, 2016 | SynCore Biotechnology Co., Ltd. | study design reconsideration | Other (stated, no rule matched) |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative… | Phase 2 | terminated | Jul 28, 2020 | EMD Serono Research & Development Institute, Inc. | The study was prematurely discontinued by the sponsor due to probability of success which was too… | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple… | Early Phase 1 | withdrawn | Jan 30, 2020 | Mayo Clinic | study was dropped | Other (stated, no rule matched) |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | — | withdrawn | Mar 2, 2020 | University of Arizona | Principal investigator is moving to a new institution. Study is closing. | Investigator |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive… | Phase 2 | withdrawn | Feb 10, 2022 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT04268693 | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer(EDC-TNBC) | — | withdrawn | Feb 13, 2020 | George Washington University | Study never initiated due to COVID pandemic, staffing changes | COVID-19 / pandemic |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and… | Phase 2 | terminated | Apr 28, 2014 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Phase 1 | terminated | Jun 17, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast… | Phase 1 | terminated | Jul 6, 2018 | M.D. Anderson Cancer Center | Due to the fact that the sponsor decided not to move forward with the development of M7824 | Sponsor / business decision |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | N/A | terminated | Nov 21, 2018 | NYU Langone Health | technical difficulties for scans on the research MRI system | Other (stated, no rule matched) |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive… | Phase 1 / Phase 2 | terminated | May 29, 2015 | Vanderbilt-Ingram Cancer Center | Interim analysis - toxicity | Safety / toxicity |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the… | Phase 2 / Phase 3 | terminated | Sep 17, 2018 | ERYtech Pharma | sponsor decision | Sponsor / business decision |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With… | Phase 2 | terminated | Mar 25, 2016 | University of Wisconsin, Madison | Study terminated early due to COVID-19 related slow enrollment and funding | COVID-19 / pandemic |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed…(0927GCC) | Phase 2 | terminated | Nov 4, 2010 | University of Maryland, Baltimore | low accrual | Enrollment / accrual |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin… | Phase 2 | terminated | Dec 1, 2016 | G1 Therapeutics, Inc. | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns | Safety / toxicity |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine… | Phase 1 | withdrawn | Apr 28, 2015 | Washington University School of Medicine | Drugs not available | Other (stated, no rule matched) |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative… | Phase 2 | terminated | Nov 7, 2018 | University of Wisconsin, Madison | Slow accrual | Enrollment / accrual |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab…(VERU-111) | Phase 2 | withdrawn | Aug 17, 2021 | Veru Inc. | Decided to halt and will potentially reopen in the future. | Other (stated, no rule matched) |
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast… | Phase 1 | terminated | Mar 5, 2020 | National Cancer Institute (NCI) | One participant was accrued, and the study was stopped due to new safety data from the company for… | Safety / toxicity |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Phase 2 | terminated | Jun 12, 2017 | BerGenBio ASA | Based on planned futility assessment | Efficacy / futility |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer… | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Immune System Key Ltd | Patients were screened but not enrolled | Enrollment / accrual |
| NCT01957514 | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative…(ITOMIC) | — | terminated | Oct 8, 2013 | University of Washington | Terminated due to loss of funding. | Funding |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive… | Phase 2 | terminated | Dec 7, 2016 | Sanofi | Study discontinued considering the limited clinical benefit combined with a higher than expected… | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple…(PANDoRA) | Phase 2 | withdrawn | Mar 13, 2019 | Cedars-Sinai Medical Center | lack of funding | Funding |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With… | Phase 2 | withdrawn | Jun 12, 2014 | Gilead Sciences | FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol… | Other (stated, no rule matched) |
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | Phase 2 | terminated | Jun 14, 2017 | University of Wisconsin, Madison | funding and slow enrollment | Enrollment / accrual |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for… | N/A | withdrawn | Aug 26, 2019 | Hebei Medical University Fourth Hospital | No patients recruited | Enrollment / accrual |
| NCT04250818 | Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on… | — | suspended | Jan 31, 2020 | Texas Tech University Health Sciences Center, El Paso | PI is moving to a new institution | Other (stated, no rule matched) |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | Phase 2 | terminated | Aug 9, 2017 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed | Enrollment / accrual |
| NCT03055312 | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative…(SYSUCC-007) | Phase 3 | terminated | Feb 16, 2017 | Sun Yat-sen University | not stated | Not stated |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced… | Phase 1 / Phase 2 | terminated | Dec 15, 2016 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Due to slow recruitment, the study had to be terminated prematurely. | Enrollment / accrual |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple… | Phase 2 | terminated | Feb 23, 2015 | GTx | Lack of Efficacy | Efficacy / futility |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and… | Phase 1 | terminated | Sep 25, 2017 | Hoffmann-La Roche | Portfolio prioritization | Sponsor / business decision |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | Phase 1 | withdrawn | Oct 29, 2019 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn from funding source. | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 8, 2023source: clinicaltrials